Mr. Simard founded XBiotech in 2005. Prior to XBiotech, he was founder and Chief Executive Officer of the therapeutic vaccine developer CTL ImmunoTherapies Corp., headquartered in Los Angeles with over 100 scientists and support staff. Mr. Simard also founded AlleCure Corp., of Valencia, California, a developer of immune-modulating therapies. In 2001, AlleCure and CTL ImmunoTherapies merged to form MannKind Corp., where Mr. Simard served as Corporate Vice President and Member of the Board. Mr. Simard invented the core technologies which form the basis for each of the commercialization programs. Operationally, he has championed an integrated approach to drug development, undertaking R&D, manufacturing and clinical regulatory programs under one roof - which he has used as an effective means to conserve capital and control timelines. Mr. Simard holds a degree in Biochemistry from the University of Saskatchewan and attended graduate studies in Medical Biophysics/Immunology at the University of Toronto. He has numerous patents related to cancer therapy, therapeutic vaccines and therapeutic antibodies, as well as substantial peer-reviewed scientific publications and the textbook "Immune Response Genes".Fabrizio Bonanni, Board Member
Dr. Fabrizio Bonanni served senior operating roles at Amgen Inc. from 1999-2012. These included Executive Vice President, Operations from (2007-2012). Prior to overseeing operations, he served as Senior Vice President, Manufacturing, Senior Vice President, Quality and Compliance. Earlier, Dr. Bonanni held various management positions at Baxter International, Inc. from 1974 to 1999, including positions as Corporate Vice President, Regulatory and Clinical Affairs and Corporate Vice President, Quality System.Thorpe McKenzie, Board Member
Mr. McKenzie is Managing Director of Pointer Management Company, Chattanooga, Tennessee, which he co-founded in 1990 to invest in hedge funds and similar types of partnerships utilizing a fund of funds approach. From 1982 until 1990, he was a private investor in New York City, and a director of several public and private companies. From 1980 until 1982, he was founding general partner of TIGER, a global hedge fund. From 1971 until 1980, he was a Vice President of Kidder, Peabody & Co., Inc. in New York. Mr. McKenzie is a graduate of the University of North Carolina in Chapel Hill, and the Wharton Graduate division of the University of Pennsylvania in Philadelphia.Hector MacKay-Dunn, LLB, QC, Board Member
Mr. MacKay-Dunn is a senior partner at Farris, Vaughan, Wills & Murphy LLP based in Vancouver with over 25 years of experience advising early stage and high growth private and public companies in a broad range of industries on domestic and cross border public and private securities offerings, mergers and acquisitions, tender offers and international partnering transactions. Mr. MacKay-Dunn advises clients in a variety of commercial industries, including biotechnology, technology, cleantech, new media, mining, transportation, personal and health fitness. Mr. MacKay-Dunn was named in the 2011 Lexpert/American Lawyer Guide to the Leading 500 Lawyers in Canada and listed in The Best Lawyers in Canada. Mr. MacKay-Dunn is immediate past Chair of the BC Innovation Council, a director of LifeSciences BC, BC Leading Edge Endowment Fund, and Tennis Canada and is also a member of the University of British Columbia Industry Liaison Advisory Council and Faculty of Science Dean's Advisory Counsel.